UCB SA (UNC BE) stock market data APIs
€161.7533
0(0%)
as of May 22, 2025
Try our APIs with
free plan!
UCB SA Financial Data Overview
There is no Profile data available for UNC.BE.
Prev. Close
161.7533
Open
161.7533
High
161.7533
Low
161.7533
52 wk Range
125.4467-196.4159
Market Cap
18 821 M
Dividends (Yield)
0.0149
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UCB SA data using free add-ons & libraries
Get UCB SA Fundamental Data
UCB SA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UCB SA News
New
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
Collaboration Blends Advanced Cloud Technologies, Open-Source Collaboration, and Data Science Integration to support UCB's development pipeline BRUSSELS and SAN FRANCISCO, May 19, 2025 /PRNewswire/ ...
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
24 scientific abstracts reflect UCB's ongoing commitment to improving outcomes for people living with neurological conditions, including rare epilepsies Dravet syndrome and Lennox-Gastaut syndrome, as...
UCB Convening Notice to the General Meeting of the Shareholders 2025
UCB CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the ordinary general meeting of the shareholders (the “General Meeting”) which will...
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Clinical data highlight survival benefits and improvement in functional motor outcomes associated with treatment with doxecitine (dC) and doxribtimine (dT) - an investigational pyrimidine nucleoside t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
